COVID-19 Deaths May Have Interfered With Results of CLL Trial
It is unclear whether adding venetoclax to treatment with ibrutinib and obinutuzumab can improve outcomes in older patients with treatment-naïve CLL.
It is unclear whether adding venetoclax to treatment with ibrutinib and obinutuzumab can improve outcomes in older patients with treatment-naïve CLL.
Cilta-cel outperformed standard care in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial.
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
The combination produced an overall response rate of 99%, and the 5-year remission rate was 76%.
The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.
Sequential nab-P/Gem-mFOLFOX improved overall survival, progression-free survival, and time to progression.
Trastuzumab deruxtecan improved progression-free and overall survival, compared with physician’s choice of therapy.
Post-induction chemoradiotherapy improved resectability, vs chemotherapy alone, in unresectable, locally advanced pancreatic cancer.
Capivasertib plus fulvestrant improved progression-free and overall survival vs fulvestrant alone.
Avasopasem manganese provided a clinically meaningful benefit to patients who developed treatment-related severe oral mucositis.